Document is current
Any future updates will be listed below
-
Authors
Teuma, E. Valas
Bucci, Frank A. Jr
Bedi, Raman
Gray, Gary
Packer, Mark http://orcid.org/0000-0003-2681-6641
-
Funding
Funding for this research was provided by:
LENSAR Inc., Orlando, Florida
- License Information
-
More Information
Article History
Received: 25 May 2021
Accepted: 26 October 2021
First Online: 1 December 2021
Declarations
:
: Not applicable. This is a porcine eye study.
: Not applicable. This is a porcine eye study.
: EVT and GG are employees of LENSAR Inc.; RB is consultant to LENSAR Inc.; FAB is a consultant to AcuFocus, Allergan, Glaukos, Johnson & Johnson, Lensar, Ocular Therapeutix, Omeros, Novartis and Physician Recommended Nutriceuticals; MP serves as advisor to Advanced Vision Science [Santen], Alcon, Amaros Medical, Aquea Health, Bausch + Lomb, Beaver-Visitec, Cassini Technologies, ClearSight, Keranova, LENSAR, LensGen, PhysIOL, Precision for Medicine, Presbia USA, Promedica International, Rayner, Refocus Group, STAAR Surgical, Tarsus Pharmaceuticals, and Visant Medical; has equity ownership in Aerie Pharmaceuticals, Amaros Medical, Aquea Health, Cassini Technologies, ClearSight, Digital Surgery Systems, Ira, Keranova, LensGen, Refocus Group, STAAR Surgical, Tarsus Pharmaceuticals, TrueVision, Visant Medical.
